STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANRO
  4. [SCHEDULE 13G/A] Alto Neuroscience Inc. SEC Filing

[SCHEDULE 13G/A] Alto Neuroscience Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ANRO logo
Alto Neuroscienc

NYSE:ANRO

ANRO Rankings

#7112 Ranked by Market Cap
N/A Ranked by Dividends

ANRO Latest News

Jun 30, 2025
Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
Jun 26, 2025
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
Jun 3, 2025
Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway
May 29, 2025
Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
May 28, 2025
Alto Neuroscience to Participate in Upcoming Investor Conferences

ANRO Latest SEC Filings

Jul 8, 2025
[Form 4] Alto Neuroscience Inc. Insider Trading Activity
Jul 8, 2025
[Form 4] Alto Neuroscience Inc. Insider Trading Activity
Jul 8, 2025
[Form 4] Alto Neuroscience Inc. Insider Trading Activity
Jul 8, 2025
[Form 4] Alto Neuroscience Inc. Insider Trading Activity
Jul 8, 2025
[8-K] Alto Neuroscience Inc. Reports Material Event

ANRO Stock Data

69.85M
24.80M
7.51%
89.72%
13.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW